Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Clin Urol. Nov 24, 2013; 2(3): 20-31
Published online Nov 24, 2013. doi: 10.5410/wjcu.v2.i3.20
Published online Nov 24, 2013. doi: 10.5410/wjcu.v2.i3.20
Integrated technologies in the post-genomic era for discovery of bladder cancer urinary markers
Sanaa Eissa, Marwa Matboli, Oncology Diagnostic Unit, Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Ain Shams University, Abassia, 11566 Cairo, Egypt
Author contributions: Both Eissa S and Matboli M contributed to this paper.
Correspondence to: Sanaa Eissa, Professor, Oncology Diagnostic Unit, Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Ain Shams University, PO Box 11381, Abassia, 11566 Cairo, Egypt. dr_sanaa_eissa@yahoo.com
Telephone: +20-100-1782828 Fax: +20-2-26859928
Received: September 29, 2013
Revised: November 10, 2013
Accepted: November 20, 2013
Published online: November 24, 2013
Processing time: 78 Days and 15.5 Hours
Revised: November 10, 2013
Accepted: November 20, 2013
Published online: November 24, 2013
Processing time: 78 Days and 15.5 Hours
Core Tip
Core tip: Capturing information from in silico data, proteomic data, gene expression data and bionanotechnology data outlines a promising approach to discover significant urinary biomarkers whose activity patterns are discriminative of bladder cancer vs control.